The application of phthalocyanine derivatives in medicine as photosensitizers for photodynamic therapy of cancer diseases is reviewed. The emphasis is on the work of Russian authors, which is less covered in the scientific literature.
Current status of phthalocyanines in the photodynamic therapy of cancer
β Scribed by Cynthia M. Allen; Wesley M. Sharman; Johan E. Van Lier
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- English
- Weight
- 101 KB
- Volume
- 05
- Category
- Article
- ISSN
- 1088-4246
- DOI
- 10.1002/jpp.324
No coin nor oath required. For personal study only.
β¦ Synopsis
Photodynamic therapy is a binary treatment now accepted in clinic for various malignancies in several countries around the world. Phthalocyanine molecules are second-generation photosensitizers with enhanced photophysical and photochemical properties over those of porphyrins. They have been shown to be phototoxic against a number of cell types and tumor models. A great deal of research has been devoted to the elucidation of their mechanism of action and mode of cell death. The present paper reviews phthalocyanine pre-clinical anti-cancer research with emphasis on phthalocyanine induced apoptosis using a silicon phthalocyanine, Pc 4. A brief summary of the latest clinical results using phthalocyanines is presented.
π SIMILAR VOLUMES
## Abstract Photodynamic therapy (PDT) has been used for the treatment of nonmalignant and malignant diseases from head to toe. Over the last decade its clinical application has gained increasing acceptance around the world. Preβclinical studies demonstrate that, in addition to the direct local cyt
A theory and method for prediction and measurement of the effective absorbed dose in photodynamic therapy of cancer is presented. The method depends on measuring the concentration of the photosensitizer (such as dihematorporphyrin ether), the flux density of the light, and the relative photodynamic